Cáncer de mama

  1. Arroyo Yustos, M.
  2. Martín Angulo, M.
  3. Álvarez-Mon Soto, M.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Título del ejemplar: Enfermedades oncológicas (IV) Cáncer de mama, tumores ginecológicos y consejo genético

Serie: 12

Número: 34

Páginas: 2011-2023

Tipo: Artículo

DOI: 10.1016/J.MED.2017.05.001 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

El cáncer de mama es el tumor más frecuente en la mujer y la principal causa de muerte por cáncer en el sexo femenino. Etiología/etiopatogenia Su etiología es multifactorial y en gran medida desconocida. Es una patología asociada al envejecimiento y a estilos de vida poco saludables, así como a los cambios en los patrones reproductivos. Clínica/diagnóstico La presentación más habitual es una masa indolora. La prueba de imagen de elección es una mamografía, y si la imagen es sospechosa de malignidad a continuación se realizará una biopsia para el diagnóstico histológico y estudio inmunohistoquímico. Pronóstico/tratamiento Su pronóstico se relaciona con el subtipo biológico y el estadio tumoral al diagnóstico. La radioterapia, la hormonoterapia y la quimioterapia adyuvante, así como las terapias biológicas en los últimos años, han conseguido una mejoría significativa en la supervivencia y calidad de vida de las pacientes. En la enfermedad metastásica las terapias tienen un papel paliativo.

Referencias bibliográficas

  • Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.
  • Dillon DA, Guidi AJ, Schnitt SJ. Pathology of invasive breast cancer. Diseases of the breast. 4ª ed. Philadelphia: Lippincott, Williams and Wilkins; 2009. p. 386.
  • Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635.
  • Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389-99.
  • Edlich RF, Winters KL, Lin KY. Breast cancer and ovarian cancer genetics. J Long Term Eff Med Implants. 2005;15(5):533-45.
  • Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2(4):475.
  • Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E.Cowden syndrome and the PTEN hamartoma tumor syndrome: system atic re-view and revised diagnostic criteria. J Natl Cancer Inst. 2013;105:1607.
  • Liedtke C, Thill M; AGO Breast Committee. AGO Recommendations for the diagnosis and treatment of patients with early breast cancer: Update 2016. Breast Care. 2016;11:216-22.
  • Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg. 2013;257:249-55.
  • Harbeck N, Salem M, Nitz U, Gluz O, Liedtke C. Personalized treatment of early stage breast cancer: present concepts and future directions. Cancer Treat Rev. 2010;36:584-94.
  • Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, for the Panel Members. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533-46.
  • Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
  • Van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW. A gene expression signature as a predictor of survival in breast cancer. N Engl JMed. 2002;347:1999-2009.
  • Albain KS, Barlow WE, Shak S, Hortobagy GN, Livingston RB, Yeh IT. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node positive, oestrogen receptor positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55-65.
  • Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen treated estrogen receptor positive breast cancer. Clin Cancer Res. 2010;16:5222-32.
  • Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17:6012-20.
  • Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER. Twenty-year follow –up of a randomized study compar-ing breast conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1233-41.
  • McLaughlin SA. Surgical management of the breast: breast conservation therapy and mastectomy. Surg Clin North Am. 2013;93:411-28.
  • Morrow M, Harris, JR, Schnitt SJ. Surgical margins in lumpectomy for breast cancer—bigger is not better. N Engl J Med. 2012;367:79-82.
  • Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early stage invasive breast cancer treated with breastconserving therapy: a meta-analysis. Ann Surg Oncol. 2014;21:717.
  • Bernet L, Piñero A, Vidal-Sicarti S, Peg V, Giménez J, Algara M. Consenso sobre la biopsia selectiva del ganglio centinela en el cáncer de mama. Revisión 2013 de la Sociedad Española de Senología y Patología Mamaria. Rev Esp Patol. 2014; 27(1):43-53.
  • Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G. Sentinellymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609-18.
  • Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB. Long term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478-88.
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011; 378(9804): 1707-16.
  • Nordenskjöld AE, Fohlin H, Albertsson P, Arnesson LG, Chamalidou C, Einbeigi Z; for the Swedish Western and Southeastern Breast Cancer Groups. No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population based study. Ann Oncol. 2015;26:1149-54.
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient level meta-analysis of randomised trials. Lancet. 2011;378:771-84.
  • Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V. Long term effects of continuing adjuvant tamoxifen to 10 years ver-sus stopping at 5 years after diagnosis of oestrogen receptor positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381: 805.
  • Gray RG, Rea D, Handley D, Bowden SJ, Perry P. aTTom: long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31s (a:5).
  • Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, for the TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107-18.
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient level meta-analysis of the randomised trials. Lancet. 2015;386: 1341-52.
  • Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol. 2016;34Suppl;abstr LBA1.
  • Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108-16.
  • González A, Lluch A, Alba E, Albanell J, Antón A, Álvarez I. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol. En prensa 2016.
  • Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R. Results of the CONFIRM phase III trial comparing fulves-trant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010; 28(30):4594-600.
  • Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T. Everolimus in postmenopausal hormone-receptor-positive ad-vanced breast cancer. N Engl J Med. 2012;366(6):520-9.
  • Ellis MJ, Bondarenko I, Trishkina E, Dvorkin M, Panasci L, Manikhas A. FALCON: a phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. Ann Oncol. 2016;27Suppl6:v552-87.
  • Finn RS, Martin M, Rugo HS, Jones SE, Im SA, Gelmon KA, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmeno-pausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol. 2016;34Suppl:507 (abstr).
  • Turner NC, Ro J, André F, Loi S, Verma S, Iwata H. Palbociclib in hormone receptor positive advanced breast cancer. N Engl J Med. 2015; 373:209-19.
  • Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists’ Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001:19(2):343-53.
  • García-Sáenz JA, Bermejo B, Estévez LG, Palomo AG, González-Farre X, Margeli M. SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol. 2015;17:939-45.
  • Harbeck N, Gnant M. Breast cancer. [Publicado online 16 noviembre 2016].
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012; 379(9814): 432-44.
  • Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project. Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-85.
  • Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cáncer (NeoSphere): a randomised multicentre, open label, phase 2 trial. Lancet Oncol. 2012;13:25-32.
  • Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Renzai M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747-56.
  • Biganzoli L, Wildiers H, Oakman C, Salat C, Denkert C, Rezai M. Management of elderly patients with breast cancer: up-dated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Special-ists (EUSOMA). Lancet Oncol. 2012;13:e148-60.
  • Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, for the CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-34.
  • Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J. for the EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91.
  • Gavila J, López-Tarruella S, Saura C, Muñoz M, Oliveira M, de la Cruz-Merino L. SEOM clinical guidelines in metastatic breast cancer 2015. Clin Transl Oncol. 2015;17:946-55.
  • Breast Imaging Reporting and Data System (BIRADS) Atlas. 4th ed. American College of Radiology, Reston, VA, 2003.51. American Joint Committee on Cancer. Cancer Staging Manual, 7ª ed. 2010.
Fuente de los datos: Dialnet